Patents Examined by Dwayne C. Jones
  • Insecticide compositions and method for destroying insects
    Patent number: 6635664
    Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether and (E)-1-(2-chlorothiazol-5-ylmethyl)-3-methyl-2-nitroguanidine as active ingredients, especially, the composition having the weight ratio of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether and (E)-1-(2-chlorothiazol-5-ylmethyl)-3-methyl-2-nitroguanidine in the composition is in the range of from 100:1 to 1:30. Further, a method for controlling pests applying an effective amount of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether and (E)-1-(2-chlorothiazol-5-ylmethyl)-3-methyl-2-nitroguanidine to pest or place where pest inhabits.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: October 21, 2003
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Satoshi Nakamura
  • Method for laminaribiose synthesis
    Patent number: 6632940
    Abstract: The invention concerns a method for preparing Laminaribiose comprising a step for glycoside binding between a donor and an acceptor of glycosyl. The invention is characterized in that the glycosyl donor is in pyranose form and corresponds to formula (II); the glycosyl acceptor is in furanose form and corresponds to formula (III); said binding step is performed in solution in an anhydrous organic solvent, at a temperature ranging between −80° C. and 40° C., for a time interval ranging between 1 minute and 8 hours, in the presence of a suitable promoter.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: October 14, 2003
    Assignee: Laboratoires Goemar
    Inventors: Jean-Claude Yvin, Frank Jamois, Vincent Ferrieres, Daniel Plusquellec
  • Inhibitors of copper-containing amine oxidases
    Patent number: 6624202
    Abstract: The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: September 23, 2003
    Assignee: Biotie Therapies Corp.
    Inventors: David John Smith, Markku Jalkanen, Ferenc Fülöp, László Lázár, Zsolt Szakonyi, Gábor Bernáth
  • Process for the isolation of galanthamine
    Patent number: 6617452
    Abstract: The subject matter of the present invention concerns a process for the isolation of the alkaloid galanthamine; the galanthamine itself which has been produced according to this process; the use of the galanthamine thus produced in galenic preparations; and the galanthamine thus produced for treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 9, 2003
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Thomas Hille, Hans-Rainer Hoffmann, Mirko Kreh, Rudolf Matusch
  • 2-methyl-thieno-benzodiazepine formulation
    Patent number: 6617321
    Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Douglas J. Allen, Kurt D. Dekemper, Thomas H. Ferguson, Stuart J. Garvin, Linda C. Murray, Norman D. Brooks, Charles A. Bunnell, Snehlata S. Mascarenhas, Sharon L. Shinkle, Barry A. Hendriksen, David E. Tupper, Manuel V. Sanchez-Felix
  • Method for treating or preventing emesis
    Patent number: 6610720
    Abstract: Alpha-2 adrenoreceptor agonists are useful for the treatment and/or prevention of emesis in patients.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: August 26, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventor: Annette Robichaud
  • Inhibition of TNF activity
    Patent number: 6608044
    Abstract: The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: August 19, 2003
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Dan Aderka, Talma Eshed (Englender)
  • Intranasal codeine for the rapid suppression of cough and rapid relief of pain
    Patent number: 6608073
    Abstract: This invention provides a method of rapidly and reliably delivering codeine, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment of pain or cough. The present invention further provides pharmaceutical compositions comprising codeine, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other analgesic and/or antitussive compounds.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: August 19, 2003
    Assignee: New Millennium Pharmaceutical Research, Inc.
    Inventors: Anwar A. Hussain, Lewis W. Dittert, Abeer M. Al-Ghananeem
  • Lyophilizate of lipid complex of water insoluble porphyrins
    Patent number: 6608050
    Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: August 19, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mathew Cherian, Shireesh Prakash Apte
  • Anti-inflammatory uses of manzamines
    Patent number: 6602881
    Abstract: The subject invention pertains to compounds which are useful as anti-inflammatory agents and to compositions containing such compounds as active ingredients. The novel uses of the compounds relate to the anti-neurogenic inflammatory properties of the disclosed compounds. Specifically exemplified herein is the use of manzamines A, B, C, D, E, and F, and their salts, analogs, and derivatives.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 5, 2003
    Assignee: Harbor Branch Oceanograhic Institution, Inc.
    Inventors: Alejandro Mayer, Sarath P. Gunasekera, Shirley A. Pomponi, Susan H. Sennett
  • Oral formulation of methylglyoxal and its imino acid conjugates for human use
    Patent number: 6596755
    Abstract: The invention relates to an oral formulation of methylglyoxal and/or its imino acid conjugates for human use and methods for preparing the compositions. Particularly, the invention relates to compositions comprising methylglyoxal and more particularly, imino acid conjugates of methylglyoxal. The present invention also relates to formulations of methylglyoxal and imino acid conjugates of methylglyoxal that can be used for the treatment and suppression of malignant diseases including but not limited to the cancers of Colon, Prostate, Pancreas, Lung, Oral cavity, Glioblastoma, and Leukemia.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: July 22, 2003
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Mukesh Kumar
  • Treatment of inner ear hair cells
    Patent number: 6593290
    Abstract: Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration, or survival of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.
    Type: Grant
    Filed: November 4, 1996
    Date of Patent: July 15, 2003
    Assignee: Genentech, Inc.
    Inventor: Wei-Qiang Gao
  • Use of magnesium based products for the treatment of neoplastic diseases
    Patent number: 6589564
    Abstract: A method of treating solid neoplastic diseases is disclosed, which involves administering to a host in need of such treatment an effective amount of a pharmaceutically acceptable magnesium salt or complex, which can be a pharmaceutically acceptable inorganic magnesium salt such as magnesium pyrophosphate, or a pharmaceutically acceptable organic magnesium salt. The composition can be administered orally, parenterally, cutaneously or mucosally, and can be given, for example, in an amount of magnesium which is from 2 to 12 mg per kg of body weight daily. Preferred compositions include magnesium lactate, magnesium aspartate, magnesium acetate, and magnesium pyrophosphate. Neoplastic diseases amenable to the method include adenocarcinoma. The method can include administering with the magnesium salt or complex an effective amount of a pharmaceutically acceptable magnesium fixing substance, such as vitamin B6.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: July 8, 2003
    Inventor: Giampiero Valletta
  • Injectable pharmaceutical formulations for partricin derivatives
    Patent number: 6586407
    Abstract: New injectable pharmaceutical formulations are described, containing a partricin derivative in the form of a free base as the active ingredient, or a pharmaceutically acceptable water-soluble salt thereof in a solubilizing/dispersing medium made up of a lipid and/or phospholipid emulsion in water, a procedure to obtain them, and the use of the formulations in the treatment of phathologies sensitive to the action of partricin derivatives.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: July 1, 2003
    Assignee: Quatex N.V.
    Inventors: Tiberio Bruzzese, Valerio Maria Ferrari
  • Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    Patent number: 6586458
    Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: July 1, 2003
    Assignee: Pozen Inc.
    Inventor: John R. Plachetka
  • Methods and kits for treating and diagnosing leiomyomas
    Patent number: 6583167
    Abstract: This invention provides methods of treating a subject suffering from a leiomyoma which comprise administering to the subject a therapeutically effective amount of an agent, or alternatively a plurality of agents, which inhibit specific metalloproteinases. This invention further provides diagnostic methods of determining whether a tumor in a subject is a leiomyoma. This invention further provides pharmaceutical compositions and kits for practicing the instant methods. Finally, this invention provides a method of determining whether an agent specifically inhibits certain metalloproteinases.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: June 24, 2003
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Stephen S. Palmer, Romana A. Nowak
  • Apparatus and method for reading gel electrophoresis pattern
    Patent number: 6576104
    Abstract: An apparatus and a method for reading a gel electrophoresis pattern can read the gel electrophoresis pattern of a sample, such as a nucleic acid and a protein, with high sensitivity and without requiring the use of an expensive device structure such as a laser light source of unique type.
    Type: Grant
    Filed: March 15, 1994
    Date of Patent: June 10, 2003
    Assignee: Hitachi Engineering Software Co., Ltd.
    Inventors: Hisanori Nasu, Yoshitaka Nakamura, Hitoshi Fujimiya, Kenji Yamamoto
  • Process for the isolation of galanthamine
    Patent number: 6573376
    Abstract: The subject matter of the present invention concerns a process for the isolation of the alkaloid galanthamine; the galanthamine itself which has been produced according to this process; the use of the galanthamine thus produced in galenic preparations; and the galanthamine thus produced for treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: June 3, 2003
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Thomas Hille, Hans-Rainer Hoffmann, Mirko Kreh, Rudolf Matusch
  • Liquid thickener for surfactant systems
    Patent number: 6573375
    Abstract: Compositions comprising alkoxylated lipophilic polyol compounds, e.g., ethoxylated, esterified methyl glucosides, are disclosed wherein at least 5% of the polyol derivatives have about three moles of the lipophilic substituent per mole of polyol. Quite advantageously, the disclosed polyol derivatives can be dissolved into aqueous solutions to provide liquid thickeners suitable for thickening surfactant-containing compositions, e.g., shampoos, at cold processing temperatures.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: June 3, 2003
    Assignee: Union Carbide Chemicals & Plastics Technology Corporation
    Inventors: Stuart Barry Polovsky, Carmella A. Barbeito, Wing Kin Li, Edward F. Diantonio, Russell Lowell Kreeger
  • Ion exchange tumor targeting (IETT)
    Patent number: 6569841
    Abstract: A compound for local, i.e. intratumoral or intracavitary administration, for targeting tumors comprising dextran, the charge of which has been modified through covalent binding of charged groups, such as charged amino acids. The compound further comprises a functional group for treating or imaging the tumor.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: May 27, 2003
    Assignee: MAP Medical Technologies OY
    Inventor: Anders Holmberg